European CHMP recommends approval of new formulation of vedolizumab

The CHMP has recommended approval of a subcutaneous formulation of vedolizumab (108mg solution for injection), for all currently authorised indications (ulcerative colitis; Crohn’s disease). It is currently only available as a powder for concentrate for solution for IV infusion.

European Medicines Agency